Antisense Therapeutics Ownership
| ATHJF Stock | USD 0.04 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Antisense |
Antisense Pink Sheet Ownership Analysis
About 19.0% of the company shares are held by company insiders. The book value of Antisense Therapeutics was presently reported as 0.03. The company recorded a loss per share of 0.01. Antisense Therapeutics had not issued any dividends in recent years. The entity had 50:49 split on the 10th of April 2018. Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia. Antisense Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.The quote for Antisense Therapeutics Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Antisense Therapeutics Limited please contact the company at 61 3 9827 8999 or go to https://www.antisense.com.au.Currently Active Assets on Macroaxis
Other Information on Investing in Antisense Pink Sheet
Antisense Therapeutics financial ratios help investors to determine whether Antisense Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antisense with respect to the benefits of owning Antisense Therapeutics security.